09 September 2021 3 Min Read
Aspen leaps on JSE as suitors offer to buy parts of its business
Interest in its active pharmaceutical ingredients operations, excluding French arm, which generated R6.4bn revenue in financial 2021
To read this article, please take a moment to register on our website – it’s quick and free.
If you’ve already registered, simply sign in.
Sign In Register